Isobenzofuran analogs of sclerophytin A
View Patent ↗Isobenzofuran analogs of sclerophytin A are prepared in a highly concise fashion via an aldol-cycloaldol sequence. The analogs exhibit IC 50 's as low as 1 μM in growth inhibitory studies against KB3 cells using an MTT assay. Preferred analogs have one of the following structural formulas, where R is hydrogen or a substituted or unsubstituted lower alkyl group and Ar is a substituted or unsubstituted aryl group.
1. A compound having a structural formula selected from the following:
wherein R represents 14, substituted lower alkyl, or unsubstituted lower alkyl; Ar represents a substituted or unsubstituted aryl; and pharmaceutically acceptable esters and salts thereof.
2. A compound of claim 1 , wherein R=methyl, ethyl, cyclopropylmethyl or cyclopentylmethyl.
3. A compound of claim 1 , wherein Ar=2-Br-phenyl, 3-Br-phenyl, 2,3-di-Cl-phenyl, 2,4-di-Cl-phenyl, 1-naphthyl, 2-pyridyl, 2-furyl, or 2-fluorophenyl.
4. A compound of claim 1 having structure 10, wherein Ar=2-fluorophenyl.
5. A method of converting (S)-(+)-carvone to an aryl glycolate compound thereof, comprising:
(i) reacting (S)-(+)-carvone with an arylaldehyde in an aldol condensation reaction to afford an aryl anti-alcohol; and
(ii) etherifying the aryl anti-alcohol to afford said aryl glycolate compound.
6. The method of claim 5 , further comprising cyclizing said aryl glycolate to afford an isobenzofuran having the structural formula
wherein R represents H, substituted lower alkyl, or unsubstituted lower alkyl; and Ar represents a substituted or unsubstituted aryl.
7. The method of claim 6 , further comprising converting by oxidative rearrangement said isobenzofuran to an enone having the structural formula
wherein R represents H, substituted lower alkyl, or unsubstituted lower alkyl; and Ar represents a substituted or unsubstituted aryl.
8. The method of claim 5 , further comprising converting by β-lactonization-decarboxylation said aryl glycolate to a diene having the structural formula
wherein Ar represents a substituted or unsubstituted aryl.
9. A method of inhibiting cell growth comprising contacting cancerous cells with a growth inhibiting amount of a compound of claim 1 , wherein the cancerous cells comprise leukemia, prostate, or non-small cell lung cancer cells.
10. A method of inhibiting cell proliferation in a patient comprising administering to the patient a proliferation-inhibiting amount of a compound of claim 1 , wherein the patient suffers from cancer comprising leukemia, prostate, or non-small cell lung cancer.